Pharmacological management of inappropriate sexual behaviours: A review of its evidence, rationale and scope in relation to men with intellectual disabilities

Journal of Intellectual Disability Research

Volumn 52, Issue 12, 2008, Pages 1078-1090

  Sajith, Sreedharan G ^a   Morgan, C ^b   Clarke, D ^b  

^a MERSEY CARE NHS TRUST   (United Kingdom)

^b University of Warwick and Coventry and Warwickshire Partnership NHS Trust   (United Kingdom)

Author keywords

Inappropriate sexual behaviour; Intellectual disability; Pharmacological management; Sexual offences

Indexed keywords

ANTIANDROGEN; BENPERIDOL; BUSPIRONE; CHLORPROMAZINE; CITALOPRAM; CYPROTERONE ACETATE; FLUOXETINE; FLUTAMIDE; FLUVOXAMINE; GONADORELIN; GOSERELIN; LEUPRORELIN; LITHIUM; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NALTREXONE; NEUROLEPTIC AGENT; PLACEBO; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTORELIN;

ADRENAL CORTEX INSUFFICIENCY; ANAPHYLAXIS; ANEMIA; ANGINA PECTORIS; BONE DEMINERALIZATION; CLINICAL TRIAL; COLD SWEAT; CUSHING SYNDROME; DEPRESSION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; FATIGUE; FLUID RETENTION; GALACTORRHEA; GALLSTONE; GYNECOMASTIA; HAIR LOSS; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPERSEXUALITY; HYPERTENSION; HYPOGONADISM; HYPOPHYSIS APOPLEXY; INFERTILITY; INTELLECTUAL IMPAIRMENT; KIDNEY DYSFUNCTION; LIBIDO; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; MALE; MASTURBATION; MUSCLE MASS; MUSCLE STIFFNESS; NIGHTMARE; ORGASM DISORDER; PEDOPHILIA; PENIS ERECTION; PSYCHOSEXUAL DISORDER; RECIDIVISM; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SADISM; SEXUAL BEHAVIOR; SEXUAL CRIME; SEXUAL DEVIATION; SIDE EFFECT; SOMNOLENCE; SPERM; SPERMATOGENESIS; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MENTAL RETARDATION; PARAPHILIAS; PSYCHOTROPIC DRUGS; SEROTONIN UPTAKE INHIBITORS; SEX OFFENSES; SEXUAL BEHAVIOR;

EID: 56649091000     PISSN: 09642633     EISSN: 13652788     Source Type: Journal    
DOI: 10.1111/j.1365-2788.2008.01097.x     Document Type: Review

References (73)

1. Adi Y., Ashcroft D., Browne K., Beech A., Fry-Smith A. & Hyde C. (2002) Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technology Assessment 6, 1-66.
2. Albin J., Vittek J., Gordon G. G., Altman K., Olivo J. & Southren A. L. (1973) On the mechanism of the anti-androgenic effect of medroxyprogesterone acetate. Endocrinology 93, 417-22.
3. Appelt M. & Floru L. (1974) The effect on sexuality of cyproterone acetate. International Pharmacopsychiatry 9, 61-76.
4. Ashman L. & Duggan L. (2002) Interventions for learning disabled sex offenders. Cochrane Database of Systematic Reviews. Issue 2. Art. No.: CD003682. DOI: 10.1002/14651858.CD003682.
5. Ashman L. & Duggan L. (2008) Interventions for learning disabled sex offenders. Cochrane Database of Systematic Reviews. Issue 1. Art. No.: CD003682. DOI: 10.1002/14651858.CD003682.pub2.
6. Baron D. P. & Unger H. R. (1977) A clinical trial of cyproterone acetate for sexual deviancy. New Zealand Medical Journal 85, 366-9.
7. Barron P., Hassiotis A. & Banes J. (2004) Offenders with intellectual disability: A prospective comparative study. Journal of Intellectual Disability Research 48, 69-76.
8. Berlin F. S. & Meinecke C. F. (1981) Treatment of sex offenders with antiandrogenic medication: Conceptualization., review of treatment modalities., and preliminary findings. American Journal of Psychiatry 138, 601-7.
9. Bradford J. M. (2001) The neurobiology, neuropharmacology and pharmacological treatment of the paraphilias and compulsive sexual behaviour. Canadian Journal of Psychiatry 46, 26-34.
10. Bradford J. M. & Pawlak A. (1993) Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Archives of sexual Behavior 22, 383-402.
11. Brahams D. (1988) Voluntary chemical castration of a mental patient. Lancet 331, 1291-2.
12. Briken P., Nika E. & Berner W. (2001) Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. Journal of Sex & Marital Therapy 27, 45-55.
13. Briken P., Hill A. & Berner W. (2003) Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: A systematic review. The Journal of Clinical Psychiatry 64, 890-7.
14. Clarke D. J. (1989) Antilibidinal drugs and mental retardation: A review. Medicine, Science, and the Law 29, 136-46.
15. Cooper A. J. (1981) A placebo-controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality. Comprehensive Psychiatry 22, 458-65.
16. Cooper A. J. (1995) Review of the role of two antilibidinal drugs in the treatment of sex offenders with mental retardation. Mental Retardation 33, 42-8.
17. Cooper A. J., Losztyn S., Russell N. C. & Cernovsky Z. (1990) Medroxyprogesterone acetate, nocturnal penile tumescence, laboratory arousal, and sexual acting out in a male with schizophrenia. Archives of sexual Behavior 19, 361-72.
18. Cooper A. J., Sandhu S., Losztyn S. & Cernovsky Z. (1992) A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles. Canadian Journal of Psychiatry 37, 687-93.
19. Davies T. S. (1970) Cyproterone acetate in sexual misbehaviour. Medicine, Science, and the Law 10, 237.
20. Davies T. S. (1974) Cyproterone acetate for male hypersexuality. Journal of International Medical Research 2, 159-63.
21. Day K. (1994) Male mentally handicapped sex offenders. The British Journal of Psychiatry 165, 630-9.
22. Fedoroff J. P. (1992) Buspirone hydrochloride in the treatment of an atypical paraphilia. Archives of Sexual Behaviour 21, 401-6.
23. Fedoroff J. P., Wisner-Carlson R., Dean S. & Berlin F. S. (1992) Medroxy-progesterone acetate in the treatment of paraphilic sexual disorders. Journal of Offender Rehabilitation 18, 109-23.
24. Gagne P. (1981) Treatment of sex offenders with medroxyprogesterone acetate. American Journal of Psychiatry 138, 644-6.
25. Gibbens T. C. & Robertson G. (1983) A survey of the criminal careers of restriction order patients. The British Journal of Psychiatry 143, 370-5.
26. Gijs L. & Gooren L. J. G. (1996) Hormonal and psychopharmacological interventions in the treatment of paraphilia: An update. Journal of Sex Research 33, 273-90.
27. Greenberg D. M., Bradford J. M. W., Curry S. & O'Rourke A. (1996) A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: A retrospective study. Bulletin of the American Academy of Psychiatry and the Law 24, 525-32.
28. Grubin D. (2007) Second expert paper: Sex offender research. NHS National Programme on Forensic Mental Health Research and Development, Liverpool, UK.
29. Hawk G., Rosenfield B. & Warren J. (1993) Prevalence of sexual offences among mentally retarded criminal defendants. Hospital and Community Psychiatry 44, 784-6.
30. Hirsch D., Kovatz S., Bernheim J. & Shenkman L. (1994) Fatal fulminant hepatitis from cyproterone acetate. Israel J Medical Sciences 30, 238-40.
31. Home Office (2007) Review of the Protection of Children from Sex Offenders. Home Office, London. Ref: 280124. CSOR.
32. Hordell A., Hill J., Forshaw N., Bendall S. & Hipkins R. (2000) Cognitive behavioural treatment of male sex offenders with intellectual disability. Journal of Intellectual Disability Research 44, 324.
33. Hucker S., Langevin R. & Bain J. (1988) A double blind trial of sex drive reducing medication in pedophiles. Sexual Abuse 1, 227-42.
34. Kafka M. P. (1994) Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: An open trial. Annals of Clinical Psychiatry 6, 189-95.
35. Kafka M. P. (1997) A monoamine hypothesis for the pathophysiology of paraphilic disorders. Archives of Sexual Behaviours 26, 343-58.
36. Kafka M. P. & Prentky R. (1992) Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. The Journal of Clinical Psychiatry 53, 351-8.
37. Kravitz H. M., Haywood T. W., Kelly J., Wahlstrom C., Liles S. & Cavanaugh J. L., Jr (1995) Medroxyprogesterone treatment for paraphiliacs. Bulletin of the American Academy of Psychiatry and the Law 23, 19-33.
38. Krueger R. B. & Kaplan M. S. (2001) Depot-leuprolide acetate for treatment of paraphilias: A report of twelve cases. Archives of Sexual Behaviour 30, 409-22.
39. Krueger R. B., Hembree W. & Hill M. (2006) Prescription of medroxyprogesterone acetate to a patient with pedophilia resulting in Cushing's syndrome and adrenal insufficiency. Sexual Abuse 18, 227-8.
40. Lane R. M. (1997) Critical review of selective serotonin reuptake inhibitor-related sexual dysfunction, incidence, possible aetiology and implications for management. Journal of Psychopharmacology 11, 72-82.
41. Lindsay W. R. (2002) Research and Literature on sex offenders with intellectual and developmental disabilities. Journal of Intellectual Disability Research 46 (Suppl. 1), 74-85.
42. Lindsay W. R., Neilson C. Q., Morrison F. & Smith A. H. (1998) The treatment of six men with a learning disability convicted of sex offences with children. British Journal of Clinical Psychology 37, 83-98.
43. Lyall I., Holland A. & Collins S. (1995) Offending by adults with learning disabilities and the attitudes of the staff to offending behaviour: Implications for service development. Journal of Intellectual Disability Research 39, 501-8.
44. McConaghy N., Blaszczynski A. & Kidson W. (1988) Treatment of sex offenders with imaginal desensitisation and/or medroxyprogesterone. Acta Psychiatrica Scandinavica 77, 199-206.
45. MacLeod T. L., Eisen A. & Sussman G. L. (1987) Anaphylactic reaction to synthetic luteinizing hormone-releasing hormone. Fertility and Sterility 48, 500-2.
46. Maletzky B. M., Tolan A. & McFarland B. (2006) The Oregon depo-Provera program: A five-year follow-up. Sexual Abuse 18, 303-16.
47. Meyer W. J. & Cole C. M. (1997) Physical and chemical castration of sex offenders: A Review. Journal of Offender Rehabilitation 25, 1-18.
48. Morsi A., Jamal S. & Silverberg J. D. (1996) Pituitary apoplexy after leuprolide administration for carcinoma of the prostate. Clinical Endocrinology 44, 121-4.
49. Mothes C., Lenhert J., Samini F. & Usher J. (1973) Chemical trial of cyproterone acetate (Androcur) in sexual deviations - collected assessments. Schering Medical News 2, 26-38.
50. Murray M. A., Bancroft J. H., Anderson D. C., Tennent T. J. & Carr P. J. (1975) Endocrine changes in male sexual deviants after treatment with anti-androgens, oestrogens or tranquillizers. Journal of Endocrinology 67, 179-88.
51. Myers B. A. (1991) Treatment of sexual offences by persons with developmental disabilities. American Journal of Mental Retardation 95, 563-9.
52. Pierce E. J. (1995) Angina pectoris and myocardial infarction with the use of leuprolide acetate. American Journal of Obstetrics Gynaecology 172, 1323.
53. Raboch J., Cerna H. & Zemeck P. (1987) Sexual aggressivity and androgens. British Journal of Psychiatry 151, 398-400.
54. Realmuto G. M. & Ruble L. A. (1999) Sexual behaviors in autism: problems of definition and management. Journal of Autism and Developmental Disorders 29, 121-7.
55. Reilly D. R., Delva N. J. & Hudson R. W. (2000) Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia. Canadian Journal of Psychiatry 45, 559-63.
56. Ross L. A., Bland W. P., Ruskin P. & Bacher N. (1987) Antiandrogen treatment of aberrant sexual activity. American Journal of Psychiatry 14, 1511.
57. Rösler A. & Witztum E. (1998) Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. New England Journal of Medicine 338, 416-22.
58. Rösler A. & Witztum E. (2000) Pharmacotherapy of paraphilias in the next millennium. Behavioural Sciences and the Law 18, 43-56.
59. Ryback R. S. (2004) Naltrexone in the treatment of adolescent sexual offenders. Journal of Clinical Psychiatry 65, 982-6.
60. Saleh F. M. & Berlin F. S. (2003) Sex hormones, neurotransmitters and psychopharmacological treatments in men with paraphilic disorders. Journal of Child Sexual Abuse 12, 233-53.
61. Schober J. M., Kuhn P. J., Kovacs P. G., Earle J. H., Byrne P. M. & Fries R. A. (2005) Leuprolide acetate suppresses pedophilic urges and arousability. Archives of Sexual Behaviour 34, 691-705.
62. Sherak D. L. (2000) Pharmacological treatment of sexually offending behavior in people with mental retardation/developmental disabilities. Mental Health Aspects of Developmental Disabilities 3, 62-74.
63. Stein D. J., Hollander E., Anthony D. T., Schneier F. R., Fallon B. A., Liebowitz M. R. et al. (1992) Serotonergic medications for sexual obsessions, sexual addictions and paraphilias. The Journal of Clinical Psychiatry 53, 267-71.
64. Tennent G., Bancroft J. & Cass J. (1974) The control of deviant sexual behavior by drugs: A double-blind controlled study of benperidol, chlorpromazine and placebo. Archives of Sexual Behaviour 3, 261-71.
65. Thibaut F., Cordier B. & Kuhn J. M. (1996) Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: A lifetime treatment? Psychoneuroendocrinology 21, 411-9.
66. Thole Z., Manso G., Salgueiro E., Revuelta P. & Hidalgo A. (2004) Hepatotoxicity induced by antiandrogens: A review of the literature. Urologia Internationalis 73, 289-95.
67. Thompson D. (1997) Profiling the sexually abusive behaviour of men with intellectual disabilities. Journal of Applied Research in Intellectual Disabilities 10, 125-39.
68. Thompson I. M. (2001) Flare associated with LHRH-agonist therapy. Reviews in Urology 3 (Suppl. 3), S10-14.
69. de Voogt H. J., Smith P. H., Pavone-Macaluso M., de Pauw M. & Suciu S. (1986) Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. Journal of Urology 135, 303-7.
70. Watanabe S., Yamasaki S., Tanae A., Hibi I. & Honna T. (1994) Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc committee on androcur users. Lancet 344, 1567-8.
71. Weinberger L. E., Sreenivasan S., Garrick T. & Osran H. (2005) The impact of surgical castration on sexual recidivism risk among sexually violent predatory offenders. Journal of American Academy of Psychiatry and the Law 33, 16-36.
72. White P., Bradley C., Ferriter M. & Hatzipetrou L. (1998) Managements for people with disorders of sexual preference and for convicted sexual offenders. Cochrane Database of Systematic Reviews. Issue 4. Art. No.: CD000251. DOI: 10.1002/14651858.CD000251.
73. Wincze J. P., Bansal S. & Malamud M. (1986) Effects of medroxyprogesterone acetate on subjective arousal, arousal to erotic stimulation and nocturnal penile tumescence in male sex offenders. Archives of Sexual Behaviour 15, 293-305.